NPS Reports Positive Phase III Extension Data For Gattex
This article was originally published in The Pink Sheet Daily
Short-bowel syndrome candidate demonstrates long-term safety and tolerability, meets efficacy endpoints.
You may also be interested in...
Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?